Clinical study of Integrum’s OPRA™ Implant System on below-knee amputations will include up to 30 patients and is fully funded by the Department of Defense

Mölndal, Sweden – November 10, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the US Department of Defense has decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial (below-knee) amputations. As previously announced,  the study will be performed by the Walter Reed National Military Medical Center in Bethesda, Maryland. Integrum will supply OPRA™ Implant Systems to Walter Reed on commercial terms.

The OPRA^TM Implant System clinical study on the below-knee amputation level recently received FDA approval, and recruitment to the study will start as soon as the protocol is approved by the Investigational Research Board (IRB). Once the study is finalized, Integrum will be able to use the data in any future regulatory process.

“We are fully committed to broadening the use of our innovative implant system to improve the lives of as many amputees as possible. We see it as a great recognition of our products’ potential that the US Department of Defense has decided to fully fund the study and that top surgeons at the Walter Reed Military Hospital will perform the surgical procedures. The results will be instrumental for a future Pre-Market Approval application for use in transtibial amputations, and we look forward to supplying OPRA^TM Implant Systems to the study,” says Rickard Brånemark, CEO of Integrum.